In a recent case, Eli Lilly and Co. v. Teva Pharmaceuticals International GmbH, the Federal Circuit upheld the validity of Teva’s patents directed to specific methods of treatment using an “effective amount” of certain antibodies. The court agreed with the Patent Trial and Appeal Board (PTAB) that the claim preambles were limiting, and that obviousness […]

{4:45 minutes to read} In a recent case, Genzyme Corp. v. Dr. Reddy’s Labs., Ltd. (Fed. Cir. 2017), the Federal Circuit affirmed the validity of patent No. 7,897,590. This patent is directed to a process to stimulate the mobilization of a donor’s bone marrow by administering both a “granulocyte-colony stimulating factor” and Plerixafor, a drug […]